Scorpius Holdings Aktie

Tivic Health Systems has acquired production and development facilities from Scorpius and established the subsidiary Velocity Bioworks, which will operate as a CDMO from San Antonio offering contract development and manufacturing services. The acquisition is supported by financing led by 3i, LP: $16 million in debt and up to $75 million in convertible preferred shares for commercialization and growth; an additional potential equity credit line of $50 million is planned. The transaction secures U.S. manufacturing of the drug candidate entolimod and is intended to reduce development and outsourcing costs. Investors reacted positively, with the stock up 16.67% for the week despite a year-to-date decline of 59.56%; at the same time the company reported substantial losses and a strategic shift in focus toward biopharmaceuticals. » Plus sur de.investing.com